Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer
These funds offer thoughtful investments in healthcare, not tactical plays.
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
More than a dozen analyst-approved foreign large-cap funds own these names.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.